Eloctate (Hemophilia A and B)：市場予測と分析（～2022）...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 7
1.2 List of Figures 7
2 Introduction 8
2.1 Catalyst 8
2.2 Related Reports 9
2.3 Upcoming Related Reports 11
3 Disease Overview 12
3.1 Etiology and Pathophysiology 12
3.1.1 Etiology 12
3.1.2 Pathophysiology 13
3.1.3 Prognosis and Quality of Life 15
3.2 Symptoms 16
3.2.1 Hemophilia A and B 16
3.2.2 Inhibitors 17
4 Disease Management 18
4.1 Treatment Overview 18
4.1.1 Hemophilia A and B Diagnosis 19
4.1.2 Hemophilia A and B Treatment 19
4.1.3 Inhibitors Diagnosis 21
4.1.4 Inhibitors Treatment 21
5 Competitive Assessment 23
5.1 Overview 23
5.2 Strategic Competitive Assessment 24
6 Opportunity and Unmet Need 28
6.1 Overview 28
6.2 Opportunities Analysis 29
6.2.1 Longer-Lasting Recombinant Factors to Reduce the Frequency of Prophylactic Injections 29
6.2.2 Lower-Cost Recombinant Replacement Therapies 30
6.2.3 Lower Risk of Inhibitor Formation in Previously Untreated Patients 31
6.2.4 More Convenient Drug Administration 31
6.2.5 Oral Formulation of Recombinant Replacement Therapies 32
6.3 Unmet Needs Gap Analysis 32
6.3.1 Long-Acting FVIII Replacement Therapies 32
6.3.2 Gene Therapy Treatments for Hemophilia A and B 33
7 Pipeline Assessment 34
7.1 Overview 34
7.2 Promising Drugs in Clinical Development – Hemophilia A 34
7.3 Promising Drugs in Clinical Development – Hemophilia B 36
7.4 Promising Drugs in Clinical Development – Hemophilia A and B Patients with Inhibitors 38
8 Eloctate (rFVIII-Fc) 39
8.1 Overview 39
8.2 Efficacy 40
8.3 Safety 41
8.4 Dosing and Formulation 41
8.5 Potential Clinical Positioning 42
8.6 Potential Commercial Positioning 43
8.7 Pricing and Reimbursement 43
8.8 SWOT Analysis 44
8.9 Forecast 44
9 Appendix 46
9.1 Bibliography 46
9.2 Abbreviations 49
9.3 Methodology 51
9.4 Forecasting Methodology 51
9.4.1 Diagnosed Hemophilia Patients 51
9.4.2 Percent Drug-Treated Patients 52
9.4.3 General Pricing Assumptions 52
9.4.4 Pricing of Pipeline Agents 53
9.5 Physicians and Specialists Included in this Study 54
9.6 About the Authors 56
9.6.1 Authors 56
9.6.2 Global Head of Healthcare 57
9.7 About GlobalData 58
9.8 Disclaimer 58